Table 2.
Real world experience with Biologics.
| Studies | N° pts | Drugs | Timing from Diagnosis to Treatment | Recurrence or Progression | Follow-Up Duration | New Primary Tumors |
|---|---|---|---|---|---|---|
| Odorici G [34] | 14 | Anti-TNFα, Anti-IL-12/23, anti-IL-17; anti-IL-23. | 3.6 y | No recurrence or progression | 34 months | (1 SCLC, 1 multiple myeloma, 1 NMSC) |
| Kahn JS [35] | 16 | Apremilast, Anti-TNFα, Anti-IL-12/23, anti-IL-17; anti IL-23. | 4.7 y | No recurrence or progression | Retrospective | None |
| Mastorino L [36] | 37 | Anti-TNFα, Anti-IL-12/23, anti-IL-17; anti-IL-23. | 7 y | No progression. 1 endometrial cancer recurrence |
33 months | None |
| Mastorino L [37] | 7 | Anti-IL-23, | 3–20 y | No recurrence or progression | 11–15 months | 1 NMSC |
| Bellinato F [38] | 12 | Anti—IL-17 | 15 m | No recurrence, 2 disease progression | 46 months | None |
| Valenti M [39] | 16 | Anti-TNFα, Anti-IL-12/23, anti-IL-17; anti-IL-23. | 5–10 y | No recurrence | 22 months | None |
| Pellegrini C [40] | 42 | Anti-IL-17 | 3.5 y | No recurrence, 2 progressions in metastatic disease | 12 months | (1 SCLC, 1 1 breast cancer, 1 glioblastoma) |